Piubelli, Chiara, Ruggiero, Alessandra 
ORCID: 0000-0001-6436-8814, Calciano, Lucia, Mazzi, Cristina, Castilletti, Concetta, Tiberti, Natalia, Caldrer, Sara, Verze, Matteo, Longoni, Silvia Stefania, Accordini, Simone et al (show 2 more authors)
(2023)
Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of infection.
EBIOMEDICINE, 89.
pp. 1-10.
|
Text
Subjects who developed SARS-CoV-2 specific IgM after vaccination show a longer humoral immunity and a lower frequency of inf.pdf - Open Access published version Download (1MB) | Preview |
Abstract
<h4>Background</h4>We have previously shown that eliciting SARS-CoV-2-specific IgM after vaccination is associated with higher levels of SARS-CoV-2 neutralizing IgG. This study aims to assess whether IgM development is also associated with longer-lasting immunity.<h4>Methods</h4>We analysed anti-SARS-CoV-2 spike protein IgG and IgM (IgG-S, IgM-S), and anti-nucleocapsid IgG (IgG-N) in 1872 vaccinees at different time points: before the first dose (D1; w0), before the second dose (D2; w3) at three (w6) and 23 weeks (w29) after D2; moreover, 109 subjects were further tested at the booster dose (D3, w44), at 3 weeks (w47) and 6 months (w70) after D3. Two-level linear regression models were used to evaluate the differences in IgG-S levels.<h4>Findings</h4>In subjects who had no evidence of a previous infection at D1 (non-infected, NI), IgM-S development after D1 and D2 was associated with higher IgG-S levels at short (w6, p < 0.0001) and long (w29, p < 0.001) follow-up. Similar IgG-S levels were observed after D3. The majority (28/33, 85%) of the NI subjects who had developed IgM-S in response to vaccination did not experience infection.<h4>Interpretation</h4>The development of anti-SARS-CoV-2 IgM-S following D1 and D2 is associated with higher IgG-S levels. Most individuals who developed IgM-S never became infected, suggesting that IgM elicitation may be associated with a lower risk of infection.<h4>Funding</h4>"Fondi Ricerca Corrente" and "Progetto Ricerca Finalizzata" COVID-2020 (Italian Ministry of Health); FUR 2020 Department of Excellence 2018-2022 (MIUR, Italy); the Brain Research Foundation Verona.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Breakthrough infection, BTN162b2 vaccine, COVID-19, IgG, IgM, SARS-CoV-2, Spike |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Systems, Molecular and Integrative Biology |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 09 Oct 2023 09:38 |
| Last Modified: | 30 Oct 2023 03:06 |
| DOI: | 10.1016/j.ebiom.2023.104471 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3173520 |
Dimensions
Dimensions
